Salla disease (SD) is an autosomal recessive disorder in which free sialic acid (N-acetyl neuraminic acid) accumulates in lysosomes. A specific transport mechanism for acidic monosaccharides on the lysosomal membrane has recently been described, but the molecular deficiency causing SD is still unknown. We have previously mapped the SD gene to 6ql4-ql5 by means of genetic linkage analysis and restricted the positive chromosomal area to less than 100 kb with linkage disequilibrium mapping. The two best allelic association markers have now retrospectively been used in five prenatal analyses originally studied with sialic acid assays in chorionic villus specimens. In four cases an unaffected fetus was predicted with a probability level ofmore than 94%, which was in concordance with the biochemical data. One fetus was predicted to be affected with over 96% probability, as was shown by free sialic acid assays in a CVS sample and in fetal tissues after termination of the pregnancy. Risk calculations incorporating disequilibrium were also used to predict the carrier status in members of six families with previous SD cases, and also in a few cases with no known family history of SD. DNA marker based analysis thus provides a reliable method for risk estimations in prenatal cases and for carrier identification of SD.
Salla disease (SD), also known as Finnish or adult type free sialic acid storage disorder (MIM 269920), is caused by accumulation of NANA (N-acetylneuraminic acid) in the lysosomes.' A specific transport mechanism for acidic monosaccharides on the lysosomal membrane has been described and a defect in the putative transport protein of NANA is the likely cause of the disease. 23 The diagnosis of SD is based on early onset psychomotor retardation associated with ataxia and some other neurological abnormalities.4 The progression of the symptoms is relatively slow and SD patients have a near normal life expectancy.56 SD is inherited as an autosomal recessive trait with exceptional enrichment in the Finnish population, particularly in the north-eastern part of the country, the Salla region. A gene frequency of 0-006 has been calculated for the whole of Finland, whereas a considerably higher frequency of 0 013 has been estimated for the high incidence area. 7 The gene frequencies in other populations are not known, but rare sporadic families have been described.89 Lysosomal accumulation of free sialic acid also leads to a phenotypically different clinical entity, the infantile type of free sialic acid storage disease (ISSD). Prenatal diagnosis of SD and ISSD has so far been based on the increased intracellular free sialic acid content in cultured amniotic fluid cells," or in CVS samples in ISSD. '2-'4 We have assigned the gene for SD to 6q1 [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] by linkage analyses in Finnish families.7 '5 The locus homogeneity of different clinical phenotypes of free sialic acid storage diseases was recently shown in patients from different ethnic backgrounds. 16 A founder effect derived linkage disequilibrium in the Finnish population is evident between the disease locus and the closest markers AFMa336zf9 and AFMb28 lwg9. Eighty-five percent of Finnish SD patients are homozygous for the [1] [2] [3] haplotype of these two microsatellite markers, and there is only one family (out of a total of 50 families) with two affected sisters who lack the 1-3 haplotype and are homozygous for the [1] [2] [3] [4] [5] [6] [7] [8] haplotype.
Here we assess the value of linkage disequilibrium in prenatal diagnosis of SD by calculating retrospectively the risks of being affected in five at risk pregnancies, which were originally studied by free sialic acid assay in uncultured CVS samples. We also applied haplotype analysis to estimate the probabilities of carrier status in family members of SD patients.
In one of the prenatal cases an affected child was predicted, whereas in four instances SD was excluded with probability levels ranging from 96 the prenatal prediction in these children. In 3 7 one case (family 3) the raised free sialic acid 34/ level in a CVS sample indicated that the fetus was affected with SD and the pregnancy was 3 7 terminated. An increased level of free sialic acid and the presence of enlarged vacuoles in several tissues of the fetus confirmed the diagnosis of SD. Aliquots of CVS samples were used retrospectively for DNA extraction and haplotype analysis using the two most closely linked markers AFMa336zf9 and AFMb28 lwg9. DNA samples from family members were stud-2 <3 ied simultaneously with the fetal samples. Pre- 7 7 diction of the fetal status was based on linkage I 3 6 analysis as described below. fig 2) requested carrier identification. In two additional families (6 and 7) haplotype analysis was performed for diagnostic purposes. The newborn baby in family 6 had no signs of SD nor any other abnormalities and the urinary free sialic acid was within normal limits. The parents had refused prenatal studies during the pregnancy. In family 7 the haplotype analysis was performed on a 9 month old male infant whose clinical and sialic acid studies had led to a strong suspicion of SD. He was hypotonic and ataxic. MRI of the central nervous system showed evidence of demyelination and the amount of free sialic acid in urine was above normal limits.
DNA SAMPLES DNA was extracted from venous blood in accordance with standard protocols and from second trimester villus biopsy specimens, which were originally taken for the determination of free sialic acid." In one case the DNA was extracted from a paraffin block using a modification of the method described by Dubeau et al. '7 Deparaffinisation and rehydration was carried out with 200 VI xylene, 600 gl 70% ethanol (twice), followed by short incubation at 55°C. After incubation a mixture of 75,l H20, 10 l lysate buffer, 5 pl 10% Tween, and 10 gl proteinase K was added and the sample was incubated overnight. The enzyme was inactivated at 95°C for 10 minutes and 3-5 ,l of the solution was used in PCR. The risk was also calculated for four newborn infants, at the request of the parents, to exclude the disease. In family 2 the baby's (7) haplotype yielded a 0% risk of being affected and the carrier probability was s 1 96%, depending on the chosen 0. The free sialic acid in the baby's urine was within the normal range. The child is now 6 months old and has shown no evidence of developmental delay or any other signs of SD. In family 3 the DNA of the twin girls (21) and (22) was extracted from the placentas after birth, and their haplotypes gave risk levels s, 1 96% of being a carrier. No urine tests have been performed. The girls are now 14 months of age and have developed normally. In family 6 the baby's (4) urine was examined shortly after birth and normal levels of free sialic acid were detected, suggesting a healthy child. DNA analysis predicted him to be an SD heterozygote, with a probability of 96 08%, compared to the risk of being affected of < 1-96%. The boy is now 16 months of age and has reached the normal milestones of development.
In family 7 the healthy mother was found to be homozygous for the [1] [2] [3] haplotype, representing so far the only 1-3 haplotype in a normal, non-SD chromosome. At the time of the DNA analysis the diagnosis of her son, the first child of unrelated parents, was still equivocal but SD was strongly suspected on the basis ofhis clinical findings. His subsequent clinical course, repeated free sialic acid assays of urine, and findings of demyelination of the central nervous system on MRI has confirmed the diagnosis of SD. The results of the haplotype analysis with [1] [2] [3] homozygosity are thus fully consistent with the phenotypic findings. However, if an unknown phenotype was assumed for the baby (as in a prenatal situation), his risk of being an SD carrier would be > 49-98% or >,41-08% and the risk of being affected ,16-87% or r8-01%, with an SD gene frequency of 0-013 or 0-006, respectively. Discussion Previous experience with the present families indicates that the determination of the level of free sialic acid (NANA) from uncultured chorionic villus samples is an accurate and reliable method for prenatal diagnosis of SD (M Renlund, personal communication). One of the five fetuses in the present study material had been found to be affected on the basis of raised free sialic acid levels in the uncultured chorionic villus sample. The pregnancy was terminated and the diagnosis was confirmed by EM and free sialic acid assays of fetal tissues. Prenatal diagnosis of SD had been attempted previously with cultured amniocytes by free sialic acid and free/total sialic acid ratio determination. " However, cultured amniotic fluid cells are not fully appropriate because the increase in NANA in SD is only moderate and the effect of the culture conditions is unknown. In ISSD, the other phenotypic manifestation of lysosomal sialic acid storage, the more pronounced rise of intracellular free sialic acid has provided an even more straightforward approach for prenatal diagnosis.2'-4
The present study shows that as a result of the assignment of the SD locus to 6q, linkage analysis is an alternative method for prenatal diagnosis. The strong linkage disequilibrium observed in the Finnish SD families with microsatellite markers AFMa336zf9 and AFMb28lwg9'6 substantially adds to the power of linkage analysis. No recombinations have yet been detected between these two markers and the SD locus. The risk haplotype 1-3 has been detected in 91% of parental Finnish SD chromosomes but only once in a normal chromosome, the mother of family 7 in the present study. The haplotype frequencies, together with the segregation of the disease in the SD families, determine the risk which is largely independent ofthe gene frequency given strong linkage disequilibrium. The 5 in our carrier studies. So far this is the only mutation event detected with markers AFMa336zf9 and AFMb281wg9 from about 500 chromosomes analysed. The estimated average mutation rate of microsatellites, 1 0-', is still relatively low22 and data from various studies suggest that microsatellites amplify accurately enough to be suitable for diagnostic studies. Our calculations were also carried out assuming a mutation frequency of 10-' for the marker AFMb281wg9 but this had no effect on the risks. A possibility remains that the only detected 1-3 non-SD haplotype in family 7 results from a new mutation either in AFMa336zf9 or AFMb28 lwg9. However, no direct evidence for this was detected when the extended haplotypes of the parents of the 1-3 homozygous mother were analysed.
In the past, carrier identification in SD was not possible. For subjects with no previous history of SD and not originating from the high risk area of Salla, a risk estimation was calculated using both gene frequencies, 0-006 and 0-013. The gene frequency estimation of 0-006 was based on the annual incidence of about two SD cases per 60000 births.7 For those with no family history of SD but originating from the high risk area, a disease gene frequency of 0-013 was used. This was based on the carrier frequency estimation of 1:40 in this area.2' However, the different gene frequencies had no significant effect on the calculated risks in these cases.
As mentioned above, the different estimates of the SD gene frequency have little effect on the risk of probabilities in the SD families because their risks are based on segregation and linkage. However, in a case of a person from the general Finnish population, the risk is based on the frequencies of the SD gene and the 1-3 risk haplotype. We can now estimate that the probability for any Finnish person carrying the 1-3 risk haplotype of being an SD carrier is approximately 33% or 51% depending on the SD gene frequency of 0-006 or 0-013. The corresponding figures for a 1-3 homozygote would be -44% or 50% of being a carrier and -10% or 25% of being affected. The probability for a subject without the 1-3 haplotype of being an SD carrier can be estimated from the haplotype frequencies in normal and SD chromosomes (table 1) . The risk associated with all other haplotypes present in both normal and SD chromosomes is very low, ranging from 0-1 to 1-5%. Accordingly, the rare haplotypes, such as 1-8 which has so far been found in SD chromosomes only, would indicate a high risk for heterozygosity but this is probably because of the limited number of chromosomes studied so far. These estimates are substantially more accurate than the predictions based on the gene frequencies alone. Haplotype analysis can therefore be used in clinical practice to predict the risk of SD. A couple who both lacked the 1-3 risk haplotype would have a low risk of bearing an affected child whereas a couple with both parents having the high risk haplotype would run a considerable risk of having a child with SD. The haplotype analysis will, however, mostly benefit the family members of the SD patients who wish to know their carrier status. As shown by the present results, haplotype analysis can give reliable predictions in most cases.
Cloning of the SD gene and identification of the mutation causing the disease will eventually replace the haplotype analysis in carrier detection and in prenatal diagnosis, at least in the Finnish population. The observed linkage disequilibrium strongly suggests that there is only one major mutation causing the disease in this founder population, as is the case with aspartylglucosaminuria and very likely also with the other genetic diseases enriched in the Finnish population. 24 The presence of only one or a few mutations would facilitate diagnostic studies and even provide the possibility for carrier screening in the general population.
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